Mechanism of Action of Human Calcitonin Gene-Related Peptide in Rabbit Heart and in Human Mammary Arteries
We investigated the effects of human calcitonin gene-related peptide (CGRP) on isolated rabbit hearts to evaluate the mechanisms responsible for the vasodilatory action of the peptide on the coronary district, monitoring contemporaneously the effects on left ventricular pressure (LVP) and heart rate...
Gespeichert in:
Veröffentlicht in: | Journal of cardiovascular pharmacology 1997-04, Vol.29 (4), p.463-470 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 470 |
---|---|
container_issue | 4 |
container_start_page | 463 |
container_title | Journal of cardiovascular pharmacology |
container_volume | 29 |
creator | Raddino, R Pelà, G Manca, C Barbagallo, M D'Aloia, A Passeri, M Visioli, O |
description | We investigated the effects of human calcitonin gene-related peptide (CGRP) on isolated rabbit hearts to evaluate the mechanisms responsible for the vasodilatory action of the peptide on the coronary district, monitoring contemporaneously the effects on left ventricular pressure (LVP) and heart rate (HR). We also evaluated the reactivity of the human internal mammary artery (IMA) to excitatory drugs acting with different mechanisms and the inhibitory response to CGRP in comparison with the commonly used vasodilatory agents. The peptide induced a slight inhibitory effect on the basal coronary perfusion pressure (CPP), whereas it was ineffective on the inotropism and chronotropism. A more detectable coronary vasodilation was evident when CPP was increased by spasmogenic agents [vasopressin, methoxamine, Bay K 8644, and prostaglandin F2α (PGF2α)]. This inhibitory effect was dose dependent (10-10 M) and apparently not specific, occurring to the same extent on different stimuli. Forskolin (10 M), an adenylate-cyclase activator, and indomethacin (1.4 × 10 M), a cyclooxygenase inhibitor, did not modify the spasmolytic activity of CGRP on precontracted coronary smooth muscle. The experiments performed on the segments of IMA, used for myocardial revascularization of patients affected by coronary diseases, have shown an evident spasmolytic action of CGRP on increased vascular tone induced by KCl (90 mM), noradrenaline (10 M), serotonin (10 M), and angiotensin II (10 M). These inhibitory responses of CGRP on the spasmogenic compounds disappeared when the endothelial function of IMA, validated by the acetylcholine test, was abolished by mechanical ablation. A series of IMA segments was incubated (30 min) with N-monomethil-L-arginine (L-NMMA), which inhibits nitric oxide (NO) synthase. In these experiments, the peptide failed to induce the vasodilation, suggesting that its action may be related to synthesis of NO. All these results show that CGRP is able to induce a potent vadodilatory action on different vessels of humans (internal mammary artery) and animals (rabbit coronary arteries). In particular the data obtained from IMA demonstrated that the vasorelaxant effect was related to synthesis of NO, one of the most studied endothelium-derived relaxing factors (EDRFs). |
doi_str_mv | 10.1097/00005344-199704000-00006 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79010730</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79010730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4346-56394ef466260a6ba1a9d15bc1ba69153411828afec17cab8beac2947515e1fc3</originalsourceid><addsrcrecordid>eNp1UU1v1DAQtRCobAs_AckHxC3FE38kOa5W0EVqBargHE2cidYlcRbbUcW_x2GXveHL2G_eGz-9YYyDuAXRVB9FPloqVUDTVELlV7FC5gXbgJayUKKUL9lGgBFFqZR5za5jfBIClK7MFbtqQBup9YY9PZA9oHdx4vPAtza52a-3_TKh5zscrUuzd57fkafikUZM1PNvdEyuJ57xR-w6l_ieMCSOvl-xk_gBpwnDb74NiYKj-Ia9GnCM9PZcb9iPz5--7_bF_de7L7vtfWGVVKbIxhpFgzKmNAJNh4BND7qz0KHJvqUCqMsaB7JQWezqjtCWjao0aILByhv24TT3GOZfC8XUTi5aGkf0NC-xrRoBopIiE-sT0YY5xkBDewxutdyCaNeY238xt5eY_0ImS9-d_1i6ifqL8Jxr7r8_9zFaHIeA3rp4oZWmNhVApqkT7Xkec0jx57g8U2gPhGM6tP9bsvwDekSTcA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79010730</pqid></control><display><type>article</type><title>Mechanism of Action of Human Calcitonin Gene-Related Peptide in Rabbit Heart and in Human Mammary Arteries</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Journals@Ovid Complete</source><source>EZB Electronic Journals Library</source><creator>Raddino, R ; Pelà, G ; Manca, C ; Barbagallo, M ; D'Aloia, A ; Passeri, M ; Visioli, O</creator><creatorcontrib>Raddino, R ; Pelà, G ; Manca, C ; Barbagallo, M ; D'Aloia, A ; Passeri, M ; Visioli, O</creatorcontrib><description>We investigated the effects of human calcitonin gene-related peptide (CGRP) on isolated rabbit hearts to evaluate the mechanisms responsible for the vasodilatory action of the peptide on the coronary district, monitoring contemporaneously the effects on left ventricular pressure (LVP) and heart rate (HR). We also evaluated the reactivity of the human internal mammary artery (IMA) to excitatory drugs acting with different mechanisms and the inhibitory response to CGRP in comparison with the commonly used vasodilatory agents. The peptide induced a slight inhibitory effect on the basal coronary perfusion pressure (CPP), whereas it was ineffective on the inotropism and chronotropism. A more detectable coronary vasodilation was evident when CPP was increased by spasmogenic agents [vasopressin, methoxamine, Bay K 8644, and prostaglandin F2α (PGF2α)]. This inhibitory effect was dose dependent (10-10 M) and apparently not specific, occurring to the same extent on different stimuli. Forskolin (10 M), an adenylate-cyclase activator, and indomethacin (1.4 × 10 M), a cyclooxygenase inhibitor, did not modify the spasmolytic activity of CGRP on precontracted coronary smooth muscle. The experiments performed on the segments of IMA, used for myocardial revascularization of patients affected by coronary diseases, have shown an evident spasmolytic action of CGRP on increased vascular tone induced by KCl (90 mM), noradrenaline (10 M), serotonin (10 M), and angiotensin II (10 M). These inhibitory responses of CGRP on the spasmogenic compounds disappeared when the endothelial function of IMA, validated by the acetylcholine test, was abolished by mechanical ablation. A series of IMA segments was incubated (30 min) with N-monomethil-L-arginine (L-NMMA), which inhibits nitric oxide (NO) synthase. In these experiments, the peptide failed to induce the vasodilation, suggesting that its action may be related to synthesis of NO. All these results show that CGRP is able to induce a potent vadodilatory action on different vessels of humans (internal mammary artery) and animals (rabbit coronary arteries). In particular the data obtained from IMA demonstrated that the vasorelaxant effect was related to synthesis of NO, one of the most studied endothelium-derived relaxing factors (EDRFs).</description><identifier>ISSN: 0160-2446</identifier><identifier>EISSN: 1533-4023</identifier><identifier>DOI: 10.1097/00005344-199704000-00006</identifier><identifier>PMID: 9156355</identifier><identifier>CODEN: JCPCDT</identifier><language>eng</language><publisher>Philadelphia, PA: Lippincott-Raven Publishers</publisher><subject>Adult ; Aged ; Animals ; Biological and medical sciences ; Blood Pressure - drug effects ; Calcitonin Gene-Related Peptide - pharmacology ; Calcitonin Gene-Related Peptide - physiology ; Calcium Channel Agonists - pharmacology ; Coronary Vessels - drug effects ; Cyclooxygenase Inhibitors - pharmacology ; Dose-Response Relationship, Drug ; Female ; Fundamental and applied biological sciences. Psychology ; Heart ; Heart - drug effects ; Heart Rate - drug effects ; Humans ; Male ; Mammary Arteries - drug effects ; Middle Aged ; Muscle Contraction - drug effects ; Muscle, Smooth, Vascular - drug effects ; Muscle, Smooth, Vascular - physiology ; Myocardial Contraction - drug effects ; Nitric Oxide - biosynthesis ; Nitric Oxide Synthase - antagonists & inhibitors ; omega-N-Methylarginine - pharmacology ; Rabbits ; Vasoconstrictor Agents - pharmacology ; Vasodilator Agents - pharmacology ; Vertebrates: cardiovascular system</subject><ispartof>Journal of cardiovascular pharmacology, 1997-04, Vol.29 (4), p.463-470</ispartof><rights>Lippincott-Raven Publishers</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4346-56394ef466260a6ba1a9d15bc1ba69153411828afec17cab8beac2947515e1fc3</citedby><cites>FETCH-LOGICAL-c4346-56394ef466260a6ba1a9d15bc1ba69153411828afec17cab8beac2947515e1fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf><![CDATA[$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&PDF=y&D=ovft&AN=00005344-199704000-00006$$EPDF$$P50$$Gwolterskluwer$$H]]></linktopdf><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00005344-199704000-00006$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>315,782,786,4613,27933,27934,64675,65470</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2686711$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9156355$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raddino, R</creatorcontrib><creatorcontrib>Pelà, G</creatorcontrib><creatorcontrib>Manca, C</creatorcontrib><creatorcontrib>Barbagallo, M</creatorcontrib><creatorcontrib>D'Aloia, A</creatorcontrib><creatorcontrib>Passeri, M</creatorcontrib><creatorcontrib>Visioli, O</creatorcontrib><title>Mechanism of Action of Human Calcitonin Gene-Related Peptide in Rabbit Heart and in Human Mammary Arteries</title><title>Journal of cardiovascular pharmacology</title><addtitle>J Cardiovasc Pharmacol</addtitle><description>We investigated the effects of human calcitonin gene-related peptide (CGRP) on isolated rabbit hearts to evaluate the mechanisms responsible for the vasodilatory action of the peptide on the coronary district, monitoring contemporaneously the effects on left ventricular pressure (LVP) and heart rate (HR). We also evaluated the reactivity of the human internal mammary artery (IMA) to excitatory drugs acting with different mechanisms and the inhibitory response to CGRP in comparison with the commonly used vasodilatory agents. The peptide induced a slight inhibitory effect on the basal coronary perfusion pressure (CPP), whereas it was ineffective on the inotropism and chronotropism. A more detectable coronary vasodilation was evident when CPP was increased by spasmogenic agents [vasopressin, methoxamine, Bay K 8644, and prostaglandin F2α (PGF2α)]. This inhibitory effect was dose dependent (10-10 M) and apparently not specific, occurring to the same extent on different stimuli. Forskolin (10 M), an adenylate-cyclase activator, and indomethacin (1.4 × 10 M), a cyclooxygenase inhibitor, did not modify the spasmolytic activity of CGRP on precontracted coronary smooth muscle. The experiments performed on the segments of IMA, used for myocardial revascularization of patients affected by coronary diseases, have shown an evident spasmolytic action of CGRP on increased vascular tone induced by KCl (90 mM), noradrenaline (10 M), serotonin (10 M), and angiotensin II (10 M). These inhibitory responses of CGRP on the spasmogenic compounds disappeared when the endothelial function of IMA, validated by the acetylcholine test, was abolished by mechanical ablation. A series of IMA segments was incubated (30 min) with N-monomethil-L-arginine (L-NMMA), which inhibits nitric oxide (NO) synthase. In these experiments, the peptide failed to induce the vasodilation, suggesting that its action may be related to synthesis of NO. All these results show that CGRP is able to induce a potent vadodilatory action on different vessels of humans (internal mammary artery) and animals (rabbit coronary arteries). In particular the data obtained from IMA demonstrated that the vasorelaxant effect was related to synthesis of NO, one of the most studied endothelium-derived relaxing factors (EDRFs).</description><subject>Adult</subject><subject>Aged</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Calcitonin Gene-Related Peptide - pharmacology</subject><subject>Calcitonin Gene-Related Peptide - physiology</subject><subject>Calcium Channel Agonists - pharmacology</subject><subject>Coronary Vessels - drug effects</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Heart</subject><subject>Heart - drug effects</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>Male</subject><subject>Mammary Arteries - drug effects</subject><subject>Middle Aged</subject><subject>Muscle Contraction - drug effects</subject><subject>Muscle, Smooth, Vascular - drug effects</subject><subject>Muscle, Smooth, Vascular - physiology</subject><subject>Myocardial Contraction - drug effects</subject><subject>Nitric Oxide - biosynthesis</subject><subject>Nitric Oxide Synthase - antagonists & inhibitors</subject><subject>omega-N-Methylarginine - pharmacology</subject><subject>Rabbits</subject><subject>Vasoconstrictor Agents - pharmacology</subject><subject>Vasodilator Agents - pharmacology</subject><subject>Vertebrates: cardiovascular system</subject><issn>0160-2446</issn><issn>1533-4023</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UU1v1DAQtRCobAs_AckHxC3FE38kOa5W0EVqBargHE2cidYlcRbbUcW_x2GXveHL2G_eGz-9YYyDuAXRVB9FPloqVUDTVELlV7FC5gXbgJayUKKUL9lGgBFFqZR5za5jfBIClK7MFbtqQBup9YY9PZA9oHdx4vPAtza52a-3_TKh5zscrUuzd57fkafikUZM1PNvdEyuJ57xR-w6l_ieMCSOvl-xk_gBpwnDb74NiYKj-Ia9GnCM9PZcb9iPz5--7_bF_de7L7vtfWGVVKbIxhpFgzKmNAJNh4BND7qz0KHJvqUCqMsaB7JQWezqjtCWjao0aILByhv24TT3GOZfC8XUTi5aGkf0NC-xrRoBopIiE-sT0YY5xkBDewxutdyCaNeY238xt5eY_0ImS9-d_1i6ifqL8Jxr7r8_9zFaHIeA3rp4oZWmNhVApqkT7Xkec0jx57g8U2gPhGM6tP9bsvwDekSTcA</recordid><startdate>199704</startdate><enddate>199704</enddate><creator>Raddino, R</creator><creator>Pelà, G</creator><creator>Manca, C</creator><creator>Barbagallo, M</creator><creator>D'Aloia, A</creator><creator>Passeri, M</creator><creator>Visioli, O</creator><general>Lippincott-Raven Publishers</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199704</creationdate><title>Mechanism of Action of Human Calcitonin Gene-Related Peptide in Rabbit Heart and in Human Mammary Arteries</title><author>Raddino, R ; Pelà, G ; Manca, C ; Barbagallo, M ; D'Aloia, A ; Passeri, M ; Visioli, O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4346-56394ef466260a6ba1a9d15bc1ba69153411828afec17cab8beac2947515e1fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Calcitonin Gene-Related Peptide - pharmacology</topic><topic>Calcitonin Gene-Related Peptide - physiology</topic><topic>Calcium Channel Agonists - pharmacology</topic><topic>Coronary Vessels - drug effects</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Heart</topic><topic>Heart - drug effects</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>Male</topic><topic>Mammary Arteries - drug effects</topic><topic>Middle Aged</topic><topic>Muscle Contraction - drug effects</topic><topic>Muscle, Smooth, Vascular - drug effects</topic><topic>Muscle, Smooth, Vascular - physiology</topic><topic>Myocardial Contraction - drug effects</topic><topic>Nitric Oxide - biosynthesis</topic><topic>Nitric Oxide Synthase - antagonists & inhibitors</topic><topic>omega-N-Methylarginine - pharmacology</topic><topic>Rabbits</topic><topic>Vasoconstrictor Agents - pharmacology</topic><topic>Vasodilator Agents - pharmacology</topic><topic>Vertebrates: cardiovascular system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raddino, R</creatorcontrib><creatorcontrib>Pelà, G</creatorcontrib><creatorcontrib>Manca, C</creatorcontrib><creatorcontrib>Barbagallo, M</creatorcontrib><creatorcontrib>D'Aloia, A</creatorcontrib><creatorcontrib>Passeri, M</creatorcontrib><creatorcontrib>Visioli, O</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiovascular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raddino, R</au><au>Pelà, G</au><au>Manca, C</au><au>Barbagallo, M</au><au>D'Aloia, A</au><au>Passeri, M</au><au>Visioli, O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanism of Action of Human Calcitonin Gene-Related Peptide in Rabbit Heart and in Human Mammary Arteries</atitle><jtitle>Journal of cardiovascular pharmacology</jtitle><addtitle>J Cardiovasc Pharmacol</addtitle><date>1997-04</date><risdate>1997</risdate><volume>29</volume><issue>4</issue><spage>463</spage><epage>470</epage><pages>463-470</pages><issn>0160-2446</issn><eissn>1533-4023</eissn><coden>JCPCDT</coden><abstract>We investigated the effects of human calcitonin gene-related peptide (CGRP) on isolated rabbit hearts to evaluate the mechanisms responsible for the vasodilatory action of the peptide on the coronary district, monitoring contemporaneously the effects on left ventricular pressure (LVP) and heart rate (HR). We also evaluated the reactivity of the human internal mammary artery (IMA) to excitatory drugs acting with different mechanisms and the inhibitory response to CGRP in comparison with the commonly used vasodilatory agents. The peptide induced a slight inhibitory effect on the basal coronary perfusion pressure (CPP), whereas it was ineffective on the inotropism and chronotropism. A more detectable coronary vasodilation was evident when CPP was increased by spasmogenic agents [vasopressin, methoxamine, Bay K 8644, and prostaglandin F2α (PGF2α)]. This inhibitory effect was dose dependent (10-10 M) and apparently not specific, occurring to the same extent on different stimuli. Forskolin (10 M), an adenylate-cyclase activator, and indomethacin (1.4 × 10 M), a cyclooxygenase inhibitor, did not modify the spasmolytic activity of CGRP on precontracted coronary smooth muscle. The experiments performed on the segments of IMA, used for myocardial revascularization of patients affected by coronary diseases, have shown an evident spasmolytic action of CGRP on increased vascular tone induced by KCl (90 mM), noradrenaline (10 M), serotonin (10 M), and angiotensin II (10 M). These inhibitory responses of CGRP on the spasmogenic compounds disappeared when the endothelial function of IMA, validated by the acetylcholine test, was abolished by mechanical ablation. A series of IMA segments was incubated (30 min) with N-monomethil-L-arginine (L-NMMA), which inhibits nitric oxide (NO) synthase. In these experiments, the peptide failed to induce the vasodilation, suggesting that its action may be related to synthesis of NO. All these results show that CGRP is able to induce a potent vadodilatory action on different vessels of humans (internal mammary artery) and animals (rabbit coronary arteries). In particular the data obtained from IMA demonstrated that the vasorelaxant effect was related to synthesis of NO, one of the most studied endothelium-derived relaxing factors (EDRFs).</abstract><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>Lippincott-Raven Publishers</pub><pmid>9156355</pmid><doi>10.1097/00005344-199704000-00006</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0160-2446 |
ispartof | Journal of cardiovascular pharmacology, 1997-04, Vol.29 (4), p.463-470 |
issn | 0160-2446 1533-4023 |
language | eng |
recordid | cdi_proquest_miscellaneous_79010730 |
source | MEDLINE; Journals@Ovid LWW Legacy Archive; Journals@Ovid Complete; EZB Electronic Journals Library |
subjects | Adult Aged Animals Biological and medical sciences Blood Pressure - drug effects Calcitonin Gene-Related Peptide - pharmacology Calcitonin Gene-Related Peptide - physiology Calcium Channel Agonists - pharmacology Coronary Vessels - drug effects Cyclooxygenase Inhibitors - pharmacology Dose-Response Relationship, Drug Female Fundamental and applied biological sciences. Psychology Heart Heart - drug effects Heart Rate - drug effects Humans Male Mammary Arteries - drug effects Middle Aged Muscle Contraction - drug effects Muscle, Smooth, Vascular - drug effects Muscle, Smooth, Vascular - physiology Myocardial Contraction - drug effects Nitric Oxide - biosynthesis Nitric Oxide Synthase - antagonists & inhibitors omega-N-Methylarginine - pharmacology Rabbits Vasoconstrictor Agents - pharmacology Vasodilator Agents - pharmacology Vertebrates: cardiovascular system |
title | Mechanism of Action of Human Calcitonin Gene-Related Peptide in Rabbit Heart and in Human Mammary Arteries |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T14%3A20%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanism%20of%20Action%20of%20Human%20Calcitonin%20Gene-Related%20Peptide%20in%20Rabbit%20Heart%20and%20in%20Human%20Mammary%20Arteries&rft.jtitle=Journal%20of%20cardiovascular%20pharmacology&rft.au=Raddino,%20R&rft.date=1997-04&rft.volume=29&rft.issue=4&rft.spage=463&rft.epage=470&rft.pages=463-470&rft.issn=0160-2446&rft.eissn=1533-4023&rft.coden=JCPCDT&rft_id=info:doi/10.1097/00005344-199704000-00006&rft_dat=%3Cproquest_cross%3E79010730%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79010730&rft_id=info:pmid/9156355&rfr_iscdi=true |